Atrial arrhythmia after transcatheter closure of secundum atrial septal defects in patients ≥40 years of age.

AIM: Data on arrhythmia outcome following device closure of atrial septal defect (ASD) are lacking. This study provides medium-term follow-up data on atrial arrhythmias in patients who were ≥40 years of age at the time of transcatheter ASD closure. METHODS AND RESULTS: It is a retrospective review. Mean age of the 159 patients was 57 years. Median follow-up was 3.6 years (range 6 months-10.9 years). Patients were classified, according to arrhythmia status prior to ASD closure, into Group I, no history of atrial arrhythmia (n = 119, mean age 55.5 years); Group II, paroxysmal atrial arrhythmia (n = 18, mean age 55.7 years); and Group III, persistent atrial fibrillation (n = 22, mean age 65.7 years). Group III patients were significantly older, had larger left atrial size, and had higher mean pulmonary arterial pressure than Group I and II patients (P < 0.001). Prior to closure, radiofrequency ablation was carried out in 12/18 (66%) of Group II and 3/22 (14%) of Group III. After device closure, 7 patients (6%) of Group I developed new atrial fibrillation. Fifty per cent (9/18) of Group II but only 9% (2/22) of Group III were in sinus rhythm on follow-up. CONCLUSION: Device closure alone in patients with persistent atrial arrhythmia is not likely to restore sinus rhythm in the medium term. New atrial arrhythmia occurred in 6% of patients who were in sinus rhythm prior to device closure. At least 50% of the patients with paroxysmal atrial arrhythmia continue to have significant atrial arrhythmia following device closure, and the role of ablation prior to closure in patients with a history of arrhythmia requires refinement.

Right ventricular disarticulation. An 18-year single centre experience.

OBJECTIVE: Right ventricular disarticulation (RVD) is an accepted procedure in the treatment of ventricular tachycardia of right ventricular origin. We set out to review the long-term outcomes with RVD at our institution for patients with arrhythmogenic right ventricular dysplasia (ARVD) or refractory tachycardia. A renewed interest in this operation has come about in patients unable to tolerate implantable cardioverter defibrillators. METHODS: Seventeen patients had RVD carried out between 1985 and 2003. There were 15 males and 2 females. The age range was 14-72 (median: 34). Six patients had partial RVD and 11 a complete RVD. ARVD was confirmed in 15 patients at histology. Biventricular pacing was used post-operatively in the two most recent patients. RESULTS: The follow-up was complete in 94% (16/17). The median follow-up was 13 years (0-18). The overall hospital mortality was 6% (1/17). Over the follow-up period there were three deaths 9, 11 and 17 years post-surgery. Heart transplantation due to biventricular failure was required in two patients. In the group followed up for more than 10 years the over all event free survival at 10 years was 77% (3/13). CONCLUSIONS: In cases of refractory ventricular tachycardia, where multiple antiarrhythmic medication, repeated catheter ablation and ICD insertion are unsuccessful at symptom control, RVD is an excellent antiarrhythmic procedure. In the long term, signs of biventricular failure present, possibly, dependent on the natural history of ARVD. The long-term effect of biventricular pacing on the disarticulated right ventricle is yet to be defined.